ASCO 2023 | Exploring the new frontier: radionuclide therapy in metastatic prostate cancer

Jeremie Calais, MD, MSc, University of California, Los Angeles, CA, discusses radionuclide therapy for metastatic prostate cancer. Radionuclide therapy, particularly in the context of metastatic prostate cancer patients, represents a new frontier in medical practice. Previously, radionuclide therapy was primarily employed for orphan diseases like neuroendocrine tumors or thyroid cancer. With the approval of pluvicto, a radiopharmaceutical for metastatic prostate cancer, the volume of patients requiring this therapy has increased significantly. This necessitates addressing various logistical challenges, including administration, staffing, training, and effective communication between medical oncologists and nuclear medicine physicians. The review paper “Incorporating radioligand therapy in clinical practice in the United States for patients with prostate cancer” offers guidance on establishing a radioligand therapy program, emphasizing the importance of collaboration, multidisciplinary work, radiation safety precautions, specific delivery logistics, and incorporating imaging findings. While there may be initial hurdles, the collaborative approach will ultimately benefit patients by optimizing the use of these techniques in their treatment. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.